5 reports of this reaction
1.3% of all ACETAMINOPHEN 325MG reports
#19 most reported adverse reaction
DISEASE PROGRESSION is the #19 most commonly reported adverse reaction for ACETAMINOPHEN 325MG, manufactured by Allegiant Health. There are 5 FDA adverse event reports linking ACETAMINOPHEN 325MG to DISEASE PROGRESSION. This represents approximately 1.3% of all 383 adverse event reports for this drug.
Patients taking ACETAMINOPHEN 325MG who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is a less commonly reported adverse event for ACETAMINOPHEN 325MG, but still significant enough to appear in the safety profile.
In addition to disease progression, the following adverse reactions have been reported for ACETAMINOPHEN 325MG:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 5 FDA reports for ACETAMINOPHEN 325MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 1.3% of all adverse event reports for ACETAMINOPHEN 325MG, making it a notable side effect.
If you experience disease progression while taking ACETAMINOPHEN 325MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.